U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07216651) titled 'WeDosify RWE Study: Personalized Semaglutide Dosing in U.S. Adults' on Oct. 10.
Brief Summary: This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a GLP-1 drug treatment such as semaglutide.
Study Start Date: Sept. 23
Study Type: OBSERVATIONAL
Condition:
Obesity & Overweight
Recruitment Status: RECRUITING
Sponsor: Closed Loop Medicine
Published by HT Digital Content Services with permission from Health Daily Digest....